ABflo® 488 Rabbit anti-Dog CD19 mAb,ABclonal,A27217

Reactivity

Dog

Application

FC

Conjugate

ABflo® 488. Ex:491nm. Em:516nm.

Platform ID

BAB555667618

ABclonal

Headquarters

500W Cummings Park, Ste. 6500 Woburn, MA 01801

Contact

Tel:
Fax:

Product Specifications
Scientific Background

Specifications

NameABflo® 488 Rabbit anti-Dog CD19 mAb
Cat. No.A27217
RRID#N/A
IsotypeIgG
ReactivityDog
ConjugationABflo® 488. Ex:491nm. Em:516nm.
ApplicationFC
Working DilutionsFC:5 μl per 10^6 cells in 100 μl volume
Clone NumberARC58534
ImmunogenRecombinant protein (or fragment).This information is considered to be commercially sensitive.
PurityAffinity purification
Appearance/FormLiquid
StorageStore at 2-8℃. Avoid freeze.; Buffer: PBS containing 0.2% BSA, preserved with proclin300 or sodium azide (as specified on the Certificate of Analysis), pH 7.3.
Regulatory StatusResearch Use Only

Scientific Background

This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.